Myopia and Pediatric Myopia Progression Market View 2026: Strong Clinical Momentum as 28 Therapeutic Candidates Advance Across Late-Stage and Mid-Stage Trials

AI Briefing

• – Myopia therapeutics market to benefit from emerging opportunities in China, advanced pipeline and FDA-approved treatments beyond atropine sulfate
• – Robust pipeline with assets in late-stage and mid-stage trials
• – Collaborative ventures and strategic alliances offer potential for market expansion